Rheumatoid Arthritis Approved for Marketing Phase Trials for Adalimumab (DB00051)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Approved for MarketingNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00650390Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab
NCT00649545Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis
NCT00650026Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis